-
Mashup Score: 0
PURPOSEMobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non–small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6
PURPOSEOutcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti–cytotoxic lymphocyte-…
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas: https://t.co/9iqmr7DDyN Co-authored by @breelynwilkyMD #sarcoma
-
-
Mashup Score: 13
PURPOSEEstablishing an accurate prognosis remains challenging in older patients with cancer because of the population’s heterogeneity and the current predictive models’ reduced ability to capture the complex interactions between oncologic and geriatric …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Machine Learning to Predict Mortality in Older Patients With Cancer: Development and External Validation of the Geriatric Cancer Scoring System Using Two Large French Cohorts https://t.co/U5SKWPalhx #GeriOnc #MachineLearning
-
-
Mashup Score: 23Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update - 6 day(s) ago
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced #OvarianCancer: ASCO Guideline update https://t.co/dOlcP025Wu
-
-
Mashup Score: 7
PURPOSERadiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk cancer.METHODSPatients had squamous cell carcinoma of the head and …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Postoperative Radiotherapy 6 Cetuximab for Intermediate-Risk #HeadandNeckCancer: https://t.co/t2ltZ0gGYv #hncsm
-
-
Mashup Score: 0
PURPOSEThe cancer/testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a promising target in myxoid/round cell liposarcoma (MRCLS).METHODSIn this pilot study, we assessed the adoptive T-cell therapy NY-ESO-1c259T letetresgene …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/ Round Cell Liposarcoma: https://t.co/YBfSShMhLi #sarcoma
-
-
Mashup Score: 26
PURPOSECyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC); …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Abemaciclib Plus Fulvestrant in Advanced #BreastCancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial: https://t.co/iMavyWN9wy
-
-
Mashup Score: 0Did I Mess Up Today? Relief and Regret After Deciding to Hang Up My Stethoscope | ASCO Publications - 13 day(s) ago
Listen to JCO Oncology Practice’s Art of Oncology Practice article,
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Listen to the latest #JCO Cancer Stories: The Art of Oncology episode "Did I Mess Up Today?” Dr. John Sweetenham shares his reflections on his shrinking clinical comfort zone from his #JCOOP article. @l_schapira #ASCODailyNews #OncTwitter ➡️ https://t.co/QiZ2AWBpvm https://t.co/DINK6wuo1P
-
-
Mashup Score: 23
PURPOSEERBB2 overexpression/amplification in RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC; human epidermal growth factor receptor 2 [HER2]-positive mCRC) appears to be associated with limited benefit from anti-EGFR antibodies and promising …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. #colorectalcancer ➡️ https://t.co/ODdKmd9P3a
-
-
Mashup Score: 6
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline ➡️ https://t.co/MgAnOtWjTg #ProstateCancer #pcsm
-
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic #NSCLC in the Phase III EXCLAIM-2 Trial: https://t.co/eoSTthBDwj #lungcancer #lcsm